Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 9 of 9 entries
View as:

Weight Management Plus LNG-IUS/Megestrol Acetate in Endometrial Atypical Hyperplasia

Phase: N/A Priority: Normal
NCT ID: NCT05316493 Org: User:
Start: 06/13/22 End: 02/28/26 Due: 02/28/27

GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT06379113 Org: User:
Start: 07/13/22 End: 03/30/25 Due: 03/30/26

Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05316467 Org: User:
Start: 05/01/22 End: 02/28/26 Due: 02/28/27

MPA Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia

Phase: N/A Priority: Normal
NCT ID: NCT03675139 Org: User:
Start: 02/26/19 End: 05/15/22 Due: 05/15/23

GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients

Phase: N/A Priority: Normal
NCT ID: NCT05316935 Org: User:
Start: 07/13/22 End: 03/30/25 Due: 03/30/26

Megestrol Acetate Plus Metformin to Megestrol Acetate in Patients With Endometrial Atypical Hyperplasia or Early Stage Endometrial Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT01968317 Org: User:
Start: 10/31/13 End: 10/31/17 Due: 10/31/18

Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia

Phase: N/A Priority: Normal
NCT ID: NCT04683237 Org: User:
Start: 03/20/21 End: 11/30/26 Due: 11/30/27

GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Atypical Hyperplasia Patients

Phase: N/A Priority: Normal
NCT ID: NCT06390904 Org: User:
Start: 07/13/22 End: 06/30/25 Due: 06/30/26

Sentinel Lymph Node Sampling for Patients With Middle-high Risk Endometrial Cancer Confined to the Uterus

Phase: N/A Priority: Normal
NCT ID: NCT04276532 Org: User:
Start: 02/13/20 End: 02/12/30 Due: 02/12/31